Project Grant R01HL172902
Award Date 8/15/26
Completion Date 4/30/31
Dollars Obligated $790K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Heart, Lung, and Blood Institute awarded The Broad Institute, Inc. $173,825 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct functional genomics research investigating gene regulatory networks in cardiac fibrosis. The award funds research to identify and characterize the transcriptional regulators that promote and maintain the activated cardiac fibroblast cell state in heart failure patients. Cardiac fibrosis—the excessive deposition of...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded The Methodist Hospital Research Institute $755,573 on August 21, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the muscle-specific E3 ligase TRIM55 in autoimmune myocarditis pathogenesis. The research uses monogenic autoimmune myocarditis models based on TREX1 deficiency to examine how innate immune responses shape disease development. The work combines in vitro studies using human...
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $248,999 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate reduced hypusination of EIF5A as a mechanism of heart failure with preserved ejection fraction (HFPEF). The research addresses mechanisms underlying HFPEF, which affects over half of heart failure patients but...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded the University of Arkansas $546,654 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for predicting and controlling cardiac fibrosis in heart failure patients with reduced ejection fraction. The project integrates systems mechanobiology modeling with experimental cell culture platforms and patient clinical data to identify cardiac fibroblast signaling feedback...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The University of Texas Health Science Center at San Antonio $118,125 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to integrate long-read and short-read RNA sequencing data to identify and characterize alternative splicing events in healthy and diseased hearts. The recipient will reconstruct heart disease-specific transcriptomes using long-read RNA sequencing data from...